company background image
MEB

MedibioASX:MEB Stock Report

Market Cap

AU$14.4m

7D

-11.1%

1Y

-27.3%

Updated

21 Oct, 2021

Data

Company Financials +
MEB fundamental analysis
Snowflake Score
Valuation1/6
Future Growth5/6
Past Performance0/6
Financial Health4/6
Dividends0/6

MEB Overview

Medibio Limited, a health technology company, researches, develops, and commercializes mental health technology to assist in the screening, diagnosing, monitoring, and management of depression and other mental health conditions in Australia and the United States.

Price History & Performance

Summary of all time highs, changes and price drops for Medibio
Historical stock prices
Current Share PriceAU$0.008
52 Week HighAU$0.007
52 Week LowAU$0.016
Beta1.61
1 Month Change0%
3 Month Change0%
1 Year Change-27.27%
3 Year Change-84.91%
5 Year Change-98.26%
Change since IPO-99.95%

Recent News & Updates

Shareholder Returns

MEBAU Healthcare ServicesAU Market
7D-11.1%1.3%1.5%
1Y-27.3%39.9%21.1%

Return vs Industry: MEB underperformed the Australian Healthcare Services industry which returned 39.9% over the past year.

Return vs Market: MEB underperformed the Australian Market which returned 21.1% over the past year.

Price Volatility

Is MEB's price volatile compared to industry and market?
MEB volatility
MEB Beta1.61
Industry Beta0.50
Market Beta1

Stable Share Price: MEB is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 15% a week.

Volatility Over Time: MEB's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Australian stocks.

About the Company

FoundedEmployeesCEOWebsite
1987n/aClaude Solitariohttps://medibio.com.au

Medibio Limited, a health technology company, researches, develops, and commercializes mental health technology to assist in the screening, diagnosing, monitoring, and management of depression and other mental health conditions in Australia and the United States. The company offers mental well-being solutions for businesses through corporate health product; and develops products for healthcare provider market. It has a clinical trial agreement with MedBridge Healthcare LLC to support sleep analysis of depressive burden (SADB) trial.

Medibio Fundamentals Summary

How do Medibio's earnings and revenue compare to its market cap?
MEB fundamental statistics
Market CapAU$14.36m
Earnings (TTM)-AU$1.49m
Revenue (TTM)AU$1.26m

11.4x

P/S Ratio

-9.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MEB income statement (TTM)
RevenueAU$1.26m
Cost of RevenueAU$170.70k
Gross ProfitAU$1.09m
ExpensesAU$2.58m
Earnings-AU$1.49m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.00082
Gross Margin86.50%
Net Profit Margin-117.57%
Debt/Equity Ratio0%

How did MEB perform over the long term?

See historical performance and comparison

Valuation

Is Medibio undervalued compared to its fair value and its price relative to the market?

0.88x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate MEB's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate MEB's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: MEB is unprofitable, so we can't compare its PE Ratio to the Global Healthcare Services industry average.

PE vs Market: MEB is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MEB's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MEB is good value based on its PB Ratio (0.9x) compared to the AU Healthcare Services industry average (4.2x).


Future Growth

How is Medibio forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

83.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MEB is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).

Earnings vs Market: MEB is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: MEB's is expected to become profitable in the next 3 years.

Revenue vs Market: MEB's revenue (64.8% per year) is forecast to grow faster than the Australian market (5.4% per year).

High Growth Revenue: MEB's revenue (64.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: MEB's Return on Equity is forecast to be low in 3 years time (12.6%).


Past Performance

How has Medibio performed over the past 5 years?

20.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MEB is currently unprofitable.

Growing Profit Margin: MEB is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MEB is unprofitable, but has reduced losses over the past 5 years at a rate of 20.6% per year.

Accelerating Growth: Unable to compare MEB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MEB is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (39.5%).


Return on Equity

High ROE: MEB has a negative Return on Equity (-9.06%), as it is currently unprofitable.


Financial Health

How is Medibio's financial position?


Financial Position Analysis

Short Term Liabilities: MEB's short term assets (A$2.7M) exceed its short term liabilities (A$963.7K).

Long Term Liabilities: MEB has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: MEB is debt free.

Reducing Debt: MEB has no debt compared to 5 years ago when its debt to equity ratio was 42.8%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MEB has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: MEB has less than a year of cash runway if free cash flow continues to reduce at historical rates of 7.4% each year


Dividend

What is Medibio current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MEB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MEB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MEB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MEB's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MEB's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.9yrs

Average management tenure


CEO

Claude Solitario

1.75yrs

Tenure

AU$242,024

Compensation

Mr. Claude Solitario is the Managing Director of Medibio Limited since January 9, 2020 and also serves its Chief Executive Officer. He has been Director at Medibio Ltd. since December 31, 2018.He served a...


CEO Compensation Analysis

Compensation vs Market: Claude's total compensation ($USD181.25K) is below average for companies of similar size in the Australian market ($USD303.55K).

Compensation vs Earnings: Claude's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: MEB's management team is considered experienced (2.9 years average tenure).


Board Members

Experienced Board: MEB's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 33.2%.


Top Shareholders

Company Information

Medibio Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Medibio Limited
  • Ticker: MEB
  • Exchange: ASX
  • Founded: 1987
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: AU$14.360m
  • Shares outstanding: 1.80b
  • Website: https://medibio.com.au

Location

  • Medibio Limited
  • 100 Albert Road
  • Level 4
  • Melbourne
  • Victoria
  • 3205
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/21 18:05
End of Day Share Price2021/10/21 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.